<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024803</url>
  </required_header>
  <id_info>
    <org_study_id>RI-MC-CT-2009</org_study_id>
    <nct_id>NCT01024803</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients</brief_title>
  <official_title>Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients: A Prospective Multicenter Clinical Study Based on Randomized Intra-individual Implant Activation in Patients With Degenerative Retinal Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Implant AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retina Implant AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients suffering from hereditary retinal degeneration receive a retinal implant to restore
      sight.

      Subretinal implant &quot;ON&quot; results in significant visual acuity improvement, when compared to
      &quot;OFF&quot; condition.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activities of daily living and mobility significantly improve with implant-ON shown via activities of daily living tasks, recognition tasks, mobility, or a combination thereof.</measure>
    <time_frame>every 3 months for a period of one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity/light-perception and/or object-recognition are significantly improved with implant-ON versus OFF as shown via: FrACT/BaLM/BaGA/VFQ-25 or a combination thereof.</measure>
    <time_frame>every 3 months for a period of one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient long term safety and stability of implant function</measure>
    <time_frame>every 3 months for a period of one year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">39</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Retinal Degeneration</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Device name: &quot;Retina Implant model Alpha&quot;. Surgical implantation of medical device into eye</intervention_name>
    <description>Surgical implantation of medical device named &quot;Retina Implant&quot; into eye to restore vision partially.
Randomized intra-individual implant activation in patient under test conditions such as: FrACT, BaLM, BaGA, maze, ADL.</description>
    <other_name>retinal implant</other_name>
    <other_name>bionic eye</other_name>
    <other_name>artificial vision</other_name>
    <other_name>artificial eye</other_name>
    <other_name>restoration of vision</other_name>
    <other_name>eye chip</other_name>
    <other_name>vision prosthesis</other_name>
    <other_name>eye implant</other_name>
    <other_name>retinal prosthesis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hereditary retinal degeneration of the outer retinal layers i.e. photoreceptor rods &amp;
             cones.

          -  Pseudophakia

          -  Angiography shows retinal vessels adequately perfused, despite pathological RP
             condition.

          -  Age between 18 and 78 years.

          -  Blindness (at least monocular) i.e. visual functions not appropriate for localization
             of objects, self sustained navigation and orientation.

          -  Ability to read normal print in earlier life, optically corrected without magnifying
             glass.

          -  Willing and able to give written informed consent in accordance to EN ISO 14155
             (section 6.7) and local legislation prior to participation in the study. Able to
             perform the study during the full time period of one year for Module-2.

        Exclusion Criteria:

          -  Period of appropriate visual functions approx. 12 years / lifetime.

          -  Optical Coherence Tomography (OCT) shows significant retina edema &amp;/or scar tissue
             within target region for implant.

          -  Retina detected as too thin to expect required rest-functionality of inner retina as
             shown via Optical Coherence Tomography (OCT).

          -  Lack of inner-retinal function, as determined by Electrically Evoked Phosphenes (EEP).

          -  Heavy clumped pigmentation at posterior pole

          -  Any other ophthalmologic disease with relevant effect upon visual function (e.g.
             glaucoma, optic neuropathies, trauma, diabetic retinopathy, retinal detachment).

          -  Amblyopia reported earlier in life on eye to be implanted

          -  Systemic diseases that might imply considerable risks with regard to the surgical
             interventions and anaesthesia (e.g. cardiovascular/ pulmonary diseases, severe
             metabolic diseases).

          -  Neurological and/or psychiatric diseases (e.g. M. Parkinson, epilepsy, depression).

          -  Hyperthyroidism or hypersensitivity to iodine

          -  Women who are pregnant or nursing, or women of childbearing potential who are not
             willing to use a medically acceptable means of birth control for the duration of the
             study, or women unwilling to perform a pregnancy test before entering the study.

          -  Participation in another interventional clinical trial within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eberhart Zrenner, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for Ophthalmology, Institute for Ophthalmic Research, University of Tuebingen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl-Ulrich Bartz-Schmidt, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Eye Hospital Tuebingen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy L Jackson, PhD FRCOphth</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>János Németh, Prof. MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology Semmelweis University Budapest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert E MacLaren, Prof. DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, John Radcliffe Hospital, Oxford, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johann Roider, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Eye Hospital, Kiel, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helmut Sachs, PD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Hospital Dresden-Friedrichstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helmut Sachs, MD, PD</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann Roider, MD, Prof.</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karl-Ulrich Bartz-Schmidt, MD, Prof.</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miklos Resch, MD, PhD</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timothy L Jackson, MB.ChB, PhD, FRCOphth</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert MacLaren, MD, Prof., DPhil DipEd FRCOphth FRCS</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <reference>
    <citation>Koitschev A, Stingl K, Bartz-Schmidt KU, Braun A, Gekeler F, Greppmaier U, Sachs H, Peters T, Wilhelm B, Zrenner E, Besch D. Extraocular Surgical Approach for Placement of Subretinal Implants in Blind Patients: Lessons from Cochlear-Implants. J Ophthalmol. 2015;2015:842518. doi: 10.1155/2015/842518. Epub 2015 Dec 10.</citation>
    <PMID>26783453</PMID>
  </reference>
  <reference>
    <citation>Hafed ZM, Stingl K, Bartz-Schmidt KU, Gekeler F, Zrenner E. Oculomotor behavior of blind patients seeing with a subretinal visual implant. Vision Res. 2016 Jan;118:119-31. doi: 10.1016/j.visres.2015.04.006. Epub 2015 Apr 20.</citation>
    <PMID>25906684</PMID>
  </reference>
  <reference>
    <citation>Stingl K, Gekeler F, Bartz-Schmidt KU, Kögel A, Zrenner E, Gelisken F. Fluorescein angiographic findings in eyes of patients with a subretinal electronic implant. Curr Eye Res. 2013 May;38(5):588-96. doi: 10.3109/02713683.2013.767349. Epub 2013 Feb 14.</citation>
    <PMID>23410193</PMID>
  </reference>
  <reference>
    <citation>Stingl K, Bartz-Schmidt KU, Besch D, Braun A, Bruckmann A, Gekeler F, Greppmaier U, Hipp S, Hörtdörfer G, Kernstock C, Koitschev A, Kusnyerik A, Sachs H, Schatz A, Stingl KT, Peters T, Wilhelm B, Zrenner E. Artificial vision with wirelessly powered subretinal electronic implant alpha-IMS. Proc Biol Sci. 2013 Feb 20;280(1757):20130077. doi: 10.1098/rspb.2013.0077. Print 2013 Apr 22.</citation>
    <PMID>23427175</PMID>
  </reference>
  <results_reference>
    <citation>Stingl K, Bartz-Schmidt KU, Besch D, Chee CK, Cottriall CL, Gekeler F, Groppe M, Jackson TL, MacLaren RE, Koitschev A, Kusnyerik A, Neffendorf J, Nemeth J, Naeem MA, Peters T, Ramsden JD, Sachs H, Simpson A, Singh MS, Wilhelm B, Wong D, Zrenner E. Subretinal Visual Implant Alpha IMS--Clinical trial interim report. Vision Res. 2015 Jun;111(Pt B):149-60. doi: 10.1016/j.visres.2015.03.001. Epub 2015 Mar 23.</citation>
    <PMID>25812924</PMID>
  </results_reference>
  <results_reference>
    <citation>Kitiratschky VB, Stingl K, Wilhelm B, Peters T, Besch D, Sachs H, Gekeler F, Bartz-Schmidt KU, Zrenner E. Safety evaluation of &quot;retina implant alpha IMS&quot;--a prospective clinical trial. Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):381-7. doi: 10.1007/s00417-014-2797-x. Epub 2014 Sep 16.</citation>
    <PMID>25219982</PMID>
  </results_reference>
  <results_reference>
    <citation>Stingl K, Bartz-Schmidt KU, Gekeler F, Kusnyerik A, Sachs H, Zrenner E. Functional outcome in subretinal electronic implants depends on foveal eccentricity. Invest Ophthalmol Vis Sci. 2013 Nov 19;54(12):7658-65. doi: 10.1167/iovs.13-12835.</citation>
    <PMID>24150759</PMID>
  </results_reference>
  <results_reference>
    <citation>Stingl K, Schippert R, Bartz-Schmidt KU, Besch D, Cottriall CL, Edwards TL, Gekeler F, Greppmaier U, Kiel K, Koitschev A, Kühlewein L, MacLaren RE, Ramsden JD, Roider J, Rothermel A, Sachs H, Schröder GS, Tode J, Troelenberg N, Zrenner E. Interim Results of a Multicenter Trial with the New Electronic Subretinal Implant Alpha AMS in 15 Patients Blind from Inherited Retinal Degenerations. Front Neurosci. 2017 Aug 23;11:445. doi: 10.3389/fnins.2017.00445. eCollection 2017.</citation>
    <PMID>28878616</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retina implant, Subretinal</keyword>
  <keyword>Legal blindness</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>Retinitis</keyword>
  <keyword>Retinal Degeneration</keyword>
  <keyword>Eye Diseases, Hereditary</keyword>
  <keyword>Retinal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

